Gilead Sciences Inc. said it is licensing its twice-yearly experimental HIV prevention drug lenacapavir to six generics ...

Gilead Sciences is wasting no time in promoting worldwide access to its twice-yearly pre-exposure prophylaxis (PrEP) HIV ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the ...

Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...

Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for ...

Despite major advances in scientific innovation, access to care and growth of health systems, there are still millions of ...

Gilead will license the HIV drug lenacapavir, a twice-yearly injectable, to six generic makers for 120 countries.

Why Gilead cut a deal with 6 generics companies around a yet-to-be-approved, twice-a-year HIV PrEP drug: "It really is all ...

Gilead Sciences has announced the signing of voluntary licencing agreements with six generic pharmaceutical manufacturers to ...

October 07, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and ...

A new licensing agreement from Gilead Sciences and six generic drug manufacturers is poised to transform HIV prevention ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...